Ask about this productRelated genes to: ApoB antibody
- Gene:
- APOB NIH gene
- Name:
- apolipoprotein B
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: ApoB antibody
Related articles to: ApoB antibody
- - Source: PubMed
Publication date: 2026/09/28
Mahmoud Dr Randa Salah Gomaa - PurposeDrusen, the hallmark of AMD, are lipoprotein-rich particles. However, the role of systemic lipid metabolism in their formation remains controversial. This meta-analysis explored the association between ApoA1, ApoA2, ApoB and Lp(a) serum levels and AMD.MethodsWe systematically searched MEDLINE, Cochrane Library, EMBASE and Scopus for relevant studies. WMD meta-analyses were performed for ApoA1 and ApoB, whereas SMD meta-analyses were conducted for ApoA2 and Lp(a) serum levels in AMD patients vs healthy controls.ResultsA total of 11 studies with 5,084 subjects for ApoA1, 4,179 for ApoB, 3,177 for ApoA2 and 3,228 for Lp(a) were included. No significant differences were observed between AMD patients (all subtypes) and controls for serum ApoA1 (WMD = 0.29 mg/dL, -3.75 to 4.32, p = 0.89), ApoB (WMD = -2.16 mg/dL, -5.67 to 1.34, p = 0.23), or Lp(a) (g: -0.14, -0.54 to 0.27, p = 0.50). ApoA2 was significantly different (g = 0.2, 0.07 to 0.34, p = 0.003). In severe AMD (geographic atrophy, neovascular AMD), meta-analysis revealed no significant difference for ApoA1 (WMD = -2.68 mg/dL, -8.87 to 3.52, p = 0.4) or ApoB (WMD = -0.42 mg/dL, -6.20 to 5.32, p = 0.89).ConclusionThis meta-analysis discovered no meaningful association between systemic levels of ApoA1, ApoB, or Lp(a) and the presence or severity of AMD. Despite a significant change in ApoA2, utilizing a Reference Change Value based interpretation, we conclude that observed differences in analyzed markers represent physiological and analytical noise rather than true biological change. Our findings suggest that systemic ApoA1, ApoB, and Lp(a) levels are not elevated in individuals with AMD, though the potential role of ApoA2 warrants further investigation. - Source: PubMed
Publication date: 2026/09/28
Arsoudi VasilikiChontos ThomasVoutsas SpyrosPetrou PetrosTyrlis KonstantinosKaravidas IoannisKandarakis Stylianos AChondrou StefaniaDiamanti SmaragdaAngelidis Constantine DGeorgalas Ilias - Apolipoprotein B (ApoB) reflects the number of circulating atherogenic lipoprotein particles and may reveal residual lipid-related risk when LDL cholesterol (LDL-C) appears normal. Whether AHA PREVENT-estimated cardiovascular risk identifies LDL-C-normal adults with discordantly high ApoB remains unclear. - Source: PubMed
Publication date: 2026/09/25
Bai MiaoYan Tongyuge - Apolipoprotein B (apoB)-containing lipoproteins contribute heterogeneously to atherosclerosis. While apoB particles are major determinants of plaque burden, Lp(a) has been linked to plaque inflammation and instability. We investigated the associations of non-Lp(a) apoB, Lp(a), and their relative balance with coronary plaque burden and vulnerability. - Source: PubMed
Publication date: 2026/09/26
Tsimikas SotiriosJanuzzi James LMaeng MichaelEngstrøm ThomasKjøller-Hansen LarsBen-Yehuda OriMatsumura MitsuakiBøtker Hans ErikFröbert OlePersson JonasWiseth RuneLarsen Alf IJensen Lisette ONordrehaug Jan EBleie ØyvindOmerovic ElmirHeld ClaesRylance RebeccaLiu YuxiJames Stefan KAli Ziad AMaehara AkikoStone Gregg WErlinge David - Familial hypercholesterolemia (FH) is most frequently caused by pathogenic variants in , but phenotypic variability suggests the influence of genetic modifiers. - Source: PubMed
Publication date: 2026/09/05
Rodríguez-Nóvoa SoniaMartínez Hernández PedroHidalgo Mayoral IreneHerranz Cecilia AmandaRodríguez Roca NeilaCarazo Álvarez AnaGallego Onís NatividadDuque Alcorta MartaRodríguez Jiménez Carmen